Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Indian CMOs are targeting new global markets. API supplier Aurobindo, through its acquisition of Actavis assets, is moving into finished generics in Western Europe.
May 1, 2014
By: Soman Harachand
Contributing Writer, Contract Pharma
As the world market for active pharmaceutical ingredients (APIs) continues to decline, India’s API sector has been growing rapidly, bolstered by growing exports to the U.S. However, Indian suppliers are actively seeking new business niches and global markets. New contract manufacturing organizations (CMOs) have recently entered the Indian API market, while Aurobindo, an established API supplier, is now moving into generic drug manufacturing in Europe through its acquisition of Actavis’ generics businesses in Western Europe. Between 2008 and 2012, global demand for API’s grew by five to six percent, 2 percent lower than it had been between 2004 and 2008, according to a report released last year by Italy’s Chemical Pharmaceutical Generic Association (CPA). India’s API production, meanwhile, more than doubled, from $2.27 billion in 2008 to $4.70 billion in 2012, the report showed. During this period, India’s API exports to the US market grew by an average of 44% per year, increasing from $255 million in 2008 to $1.12 billion in 2012. Increased M&A Activity in 2013 and 2014 Last year, there were major mergers and acquisitions in this field, including Mylan Labs’ acquisition of Strides, and Hospira’s of Orchid. This year, Aurobindo Pharma bought Actavis Plc’s (Dublin) generics commercial operations in seven Western European markets. Aurobindo claims about 150 DMFs with FDA and over 2,000 filings in other markets. With more than 200 APIs, Aurobindo aims to offer a varied set of products including sterile and non-sterile penicillin, cephalosporins and penems, and company managers say they are working to improve operational efficiencies and reduce costs. Aurobindo is based in Hyderabad, in southern India, a city which is a hub for API manufacturers. The company’s senior managers hope that the Actavis acquisition will allow it to enter the Top 10 list of European producers in several key markets. They also see the buy as a way to ensure a long-term supply of APIs from India. Will Actavis Acquisition Put Aurobindo in Europe’s Top 10? The acquired business units had been running losses, but their new owner plans to integrate them with its existing manufacturing capabilities. Apart from nine API factories, Aurobindo has over half a dozen formulation facilities and is one of the top ANDA filers from India. But others are entering India’s API business. GVK Bio, known mainly as a contract research organization (CRO) plans to move into manufacturing with a $16.5-million API facility in the southeastern city of Vizag. Due to come online in two years, the new API center, with nearly 200,000-L of capacity, is meant to increase the company’s manufacturing revenues, now less than 40% of the total. The company recently started up a manufacturing facility for formulations, as well, in Bangalore. GVK, which gets nearly half of its earnings from drug discovery services, bought California’s Aragen Bioscience, a preclinical CRO specializing in biologics services, in February. In April, the CMO, Neuland Pharma, started up its new API facility in Hyderabad, with funding from Tokyo-based API Corporation (APIC), a healthcare unit of Mitsubishi Chemical Holdings Group. The plant will supply API’s and intermediates to the Japanese firm as part of an agreement reached a year ago.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !